Our science

The Innate Immune System

Innate immunity is the first line of defense and coordinates the more complex and specialized adaptive immune system. In addition to defense, the innate immune system provides various levels of support to cells and systems within the body that are necessary for normal function. The consequences of a poorly functioning innate immune system are broad and implicated in nearly every disease.

What makes us Different?

The immune system is a double-edged sword: it both protects and poses a threat. The same cells and molecules that are implicated in disease are essential to normal function and repair.

Rather than wielding a sledgehammer that broadly modifies immune activity, we need a scalpel—treatments that are finely tuned to reprogram the immune system in a manner that mitigates disease without forsaking its protective roles and compromises safety.

INmune Bio is targeting two key components of the innate immune system to treat Neurologic Disease and Cancer:

XPro1595 targeting Tumor Necrosis Factor

INKmune targeting Natural Killer cells

Our therapies are designed to restore the normal function of the innate immune system so that the body can heal itself.

Tumor Necrosis Factor (TNF)

Is a master regulator of the innate immune system. TNF dysfunction has been linked to many diseases including Neurologic diseases and Cancer. Reestablishing normal TNF function is a key approach for treating many diseases.

XPro1595

XPro1595 is a next-generation, precision targeted therapy that neutralizes the form of TNF that drives innate immune dysfunction, chronic inflammation, and disease. XPro1595 does not interfere with the form of TNF that promotes normal function and repair. This specificity greatly improves the effectiveness and safety.

XPro1595 is currently being developed for Alzheimer’s Disease and Cancer.

See how XPro1595 works

XPro1595 Publications

Natural Killer (NK) Cells

Are the principal cells responsible for detecting cancer. NK Cell dysfunction increases lifetime risk of cancer. Restoring NK Cell function is the aim of many immunotherapy companies.

INKmune

INKmune is unique. INKmune works within the body to activate the patients own NK cells against multiple forms of cancer.

Unlike other NK Cell treatments that require external manipulations or priming by extrinsic factors (i.e., cytokines) that cause off-target and often toxic side effects, INKmune is administered directly to the patient and activates only the patient’s resting NK cells.

This specificity greatly improves safety. CaRe Prostate is the first cancer immunotherapy trial approved for administration on an outpatient basis.

INKmune is currently being developed for metastatic castration resistant prostate cancer.

See how INKmune works

INKmune Publications

Our Publications

Xpro1595 Publications

View Documents

INKmune Publications

View Documents